

Inpharmatica (London) has appointed **Andrew Ayscough** as director of chemistry. Dr. Ayscough was previously director of research at British Biotech Pharmaceuticals. In addition, the company has announced that a team of seven medicinal chemists has been recruited from Millennium Pharmaceuticals. The team will be based at Inpharmatica's recently acquired Cambridge, UK, facility.

Active Pass Pharmaceuticals (Vancouver, BC, Canada) has announced that **Rod Campbell** is leaving his position as CFO to pursue other opportunities. Concurrent with his departure, **Jeff Tomlinson** has been appointed chief business officer. Mr. Tomlinson served as director of strategic marketing and business development at Gene Logic, and in 2001, moved to GrowthWorks Capital, where he was vice president of investments.

Resverlogix (Calgary, Alberta, Canada) has appointed **William A. Cochrane** chairman of its board of directors. A board member since May 2002, Dr. Cochrane is a former president of the University of Calgary, and has served as CEO and chairman of Connaught Laboratories and Stressgen Biotechnologies. He currently serves on the boards of Oncolytics Biotech, Andre's Wines, Pheromone Sciences, Nucleus Bio Sciences, Medicare and Fox Energy.

Mark Egerton has joined Oxagen (Abingdon, UK) as chief commercial officer and a member of the board. His most recent position was CEO of Cyprotex, and he also served as vice president of European business operations for Incyte.

The Biotechnology Industry Organization (BIO; Washington, DC, USA) has named **Barbara Glenn** director of animal biotechnology and **Hannah Highfill** director for international market access. Additionally, **Michael J. Phillips** has been promoted to vice president, food and agriculture, science and regulatory policy. Dr. Glenn comes to BIO from the Federation of Animal Science Societies, where she served as executive vice president and chief scientific advisor. Ms. Highfill served most recently as the manager of international biotechnology education at the US Grains Council, and previously as a legislative correspondent for US Senator Max Baucus (D-MT). Dr. Phillips most recently served as BIO's executive director, food and agriculture.

Paul H. Johnson has joined Natestch Pharmaceutical (Bothell, WA, USA) as senior vice president, research and development,

and chief scientific officer. Dr. Johnson was previously vice president, research and development, and chief scientific officer at EpiGenX Pharmaceuticals.

Argenta Discovery (Harlow, UK) has announced the appointment of **Richard Lingard** as vice president, business development. He was previously director of business development at Inpharmatica.

Five Prime Therapeutics (S. San Francisco, CA, USA) has named **Gail J. Maderis** president and CEO. Ms. Maderis was previously corporate vice president of Genzyme and president of Genzyme Molecular Oncology. She is a member of the advisory board of the Harvard Business School Alumni Biotechnology Roundtable, and previously served on the board of directors of the New York Pharma Forum and the scientific advisory board of the Canadian Medical Discoveries Funds. **Lewis T. Williams**, the founder of Five Prime Therapeutics, will continue in his role as executive chairman and as leader of the company's research efforts.

Sean Marett has been named vice president of business development and a member of the board at Lorantis (Cambridge, UK). He joins the company from Evotec OAI, where he served as chief business officer.

ARIAD Pharmaceuticals (Cambridge, MA, USA) has announced that **Paul J. Sekhri**, former senior vice president in the global business development and licensing group at Novartis Pharma, has been appointed to the newly created position of president and chief business officer. Most recently, he was a partner at the Sprout Group, the venture capital arm of Credit Suisse First Boston. ARIAD has also named **Athanase Lavidas**, chairman and CEO of the Lavipharm Group, to its board of directors. Finally, the following promotions have been announced: **Timothy Clackson** is ARIAD's new chief scientific officer, **John Iuliucci** has been named chief development officer, and **Tomi Sawyer** has been promoted to senior vice president, drug discovery.



Microscience (Berkshire, UK) has appointed **John St. Clair Roberts** as medical director and as a member of the board of directors. Dr. St. Clair Roberts previously held the same positions at Xenova, and he served as medical director at Cantab.